R Moses

Summary

Affiliation: University of Wollongong
Country: Australia

Publications

  1. ncbi Repaglinide in combination therapy
    R Moses
    University of Wollongong, New South Wales, Australia
    Diabetes Nutr Metab 15:33-8. 2002
  2. ncbi Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
    R Moses
    Department of Endocrinology, Illawarra Regional Hospital, Wollongong, Australia
    Diabetes Care 22:119-24. 1999
  3. ncbi Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
    G R Dagenais
    Laval University Heart and Lung Institute, 2725 Chemin Ste Foy, Quebec, Quebec City, Canada
    Diabetes Care 31:1007-14. 2008
  4. ncbi Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    Anushka Patel
    N Engl J Med 358:2560-72. 2008

Detail Information

Publications4

  1. ncbi Repaglinide in combination therapy
    R Moses
    University of Wollongong, New South Wales, Australia
    Diabetes Nutr Metab 15:33-8. 2002
    ..In conclusion, repaglinide has additive, and often synergistic, effects on glycaemic control when given in combination regimens and should be a valuable option in the management of patients with T2DM...
  2. ncbi Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes
    R Moses
    Department of Endocrinology, Illawarra Regional Hospital, Wollongong, Australia
    Diabetes Care 22:119-24. 1999
    ..To compare the effect of repaglinide in combination with metformin with monotherapy of each drug on glycemic control in patients with type 2 diabetes...
  3. ncbi Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial
    G R Dagenais
    Laval University Heart and Lung Institute, 2725 Chemin Ste Foy, Quebec, Quebec City, Canada
    Diabetes Care 31:1007-14. 2008
    ..We determined the effects of ramipril and rosiglitazone on combined and individual CVD and renal outcomes in people with IGT and/or IFG in the Diabetes REduction Assessment With ramipril and rosiglitazone Medication (DREAM) trial...
  4. ncbi Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
    Anushka Patel
    N Engl J Med 358:2560-72. 2008
    ..5% yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events, primarily as a consequence of a 21% relative reduction in nephropathy. (ClinicalTrials.gov number, NCT00145925.)..